Association of SGLT2 inhibitors with incident cancer
Main finding · Incident cancerResult — go to the resultHazard ratio 0.80 95 % CI 0.70–0.91Authors' conclusion
Our investigation using nationwide real-world data demonstrated the potential advantage of SGLT2i over DPP4i in reducing the development of cancer in individuals with diabetes.
Study context
- Population
- Individuals with diabetes newly prescribed SGLT2i or DPP-4i, large-scale epidemiological databasepropensity-matched, analysed
- Participants
- 26,823 individuals
- Exposure
- SGLT2i vs DPP-4i
- SGLT2in = 8,941
- DPP4in = 17,882reference
- Outcome
- Incidence of cancer
- Follow-up
- Mean 2.0 ± 1.6 years
Methodological details1:2 propensity score matching, large-scale epidemiological database
- 1:2 propensity score matching
- Large-scale epidemiological database
Main finding
Incident cancer
Hazard ratio
0.80
95 % CI 0.70–0.91
SGLT2ivs DPP4i
HR 0.80 (95 % CI 0.70–0.91)
As reported in the abstract
- Individuals who developed cancer (total)
- 1,076
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| Colorectal cancer | 0.71 (0.50–0.998) | |
| Cancer, sensitivity analysis: overlap weighting | 0.79 (0.66–0.94) | |
| 0.512Hazard ratio (log scale) |
| Outcome | Estimate |
|---|---|
| Cancer, sensitivity analysis: inverse probability of treatment weighting | 0.75 (95 % CI 0.65–0.86) |
| Cancer, sensitivity analysis: induction period settings | 0.78 (95 % CI 0.65–0.93) |
Cancer risk among individual SGLT2is
- Risk of cancer comparable among individual SGLT2is
- P-value of 0.1738
Original publication
Association of SGLT2 inhibitors with incident cancer. Diabetes Metab. Published 24 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →